Verdiva Bio Limited announced the appointment of Steve Marso, M.D. as Chief Medical Officer. This move is aimed at strengthening the company's leadership team with his extensive clinical and regulatory experience.
Who to call at Verdiva Bio, and when
A new leader at Verdiva Bio brings new priorities and often new vendors. The first weeks are when they listen.
An alert the day Verdiva Bio raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Verdiva Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Verdiva Bio. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Verdiva Bio
Location
London, England, United Kingdom
About
Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva’s most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia, which also confirmed the viability of once-weekly dosing. The Company is also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy, improved tolerability, and healthier weight loss. The Verdiva team will harness the emerging science in gut-brain biology and leverage their history of successful drug development to advance novel therapeutic options aiming to transform the lives of millions living with obesity worldwide.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Verdiva Bio changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
LondonBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma